- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 10.07. | NSE - REVIVA PHARMACEUTICALS HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 5 | SEC Filings | ||
| 13.05. | Reviva Pharmaceuticals GAAP EPS of -$0.46 misses by $0.11 | 3 | Seeking Alpha | ||
| 13.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 13.05. | Reviva Pharmaceuticals: Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | 388 | GlobeNewswire (Europe) | - Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form... ► Artikel lesen | |
| 13.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 15.04. | Reviva Pharmaceuticals sichert sich 10 Mio. US-Dollar und verlängert finanzielle Reichweite bis Q1 2027 | 1 | Investing.com Deutsch | ||
| 15.04. | Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 | 1 | Investing.com | ||
| 15.04. | Reviva Pharmaceuticals: Reviva Announces Letter to Shareholders | 611 | GlobeNewswire (Europe) | CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies... ► Artikel lesen | |
| 15.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | Reviva Pharmaceuticals: Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | 382 | GlobeNewswire (Europe) | - Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia - - Current data package highlights... ► Artikel lesen | |
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 28.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 25.03. | Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split | 2 | Insider Monkey | ||
| 25.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering | 208 | GlobeNewswire (Europe) | CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that... ► Artikel lesen | |
| 23.03. | Reviva Pharmaceuticals raises $10 million in public offering | 1 | Investing.com | ||
| 23.03. | Reviva Pharmaceuticals schließt Kapitalerhöhung über 10 Millionen US-Dollar ab | 4 | Investing.com Deutsch | ||
| 19.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 19.03. | Reviva Pharmaceuticals prices $10M public offering at $1.50 | 3 | Investing.com | ||
| 19.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,250 | +2,40 % | Wirkstoffe, Zukäufe, Aufspaltungen: Werden Bayer, Novo Nordisk, BioNxt oder Evotec zu Top-Übernahme-Kandidaten? | Nach einer jahrelangen Konsolidierung fragen sich Investoren: Geht es auch mal wieder aufwärts? Der globale LifeScience-Sektor steht auch im Jahr 2026 vor einer massiven Konsolidierungswelle, da etablierte... ► Artikel lesen | |
| NOVO NORDISK | 41,140 | +1,78 % | Novo Nordisk steigert Quartalsgewinn und hebt Prognosen an | ||
| ROCHE | 384,24 | +0,69 % | Wie gelingt medizinischer Fortschritt auch morgen? / Patientenbeteiligung, KI und Strukturreformen beim 5. Roche Summer Summit | Grenzach-Wyhlen (ots) - Patient:innen bringen ihre Perspektive heute frühzeitig und konkret in Forschung, klinische Studien und Versorgung ein. Gleichzeitig geraten die Rahmenbedingungen unter Druck... ► Artikel lesen | |
| VIATRIS | 15,310 | -0,01 % | Weekly Buzz: Cipla, Viatris Win FDA Nod; Boston Scientific Cuts Jobs; argenx Snaps Up Forte Biosciences; Johnson & Johnson, GSK Strike Deals | NEW BRUNSWICK (dpa-AFX) - The healthcare sector delivered another eventful week, marked by major regulatory approvals, strategic partnerships, acquisitions, restructuring initiatives and significant... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,400 | -0,78 % | Green Thumb Industries Q2 2026 Earnings Preview | ||
| QUANTUM BIOPHARMA | 2,500 | +6,20 % | Quantum BioPharma Announces Closing of Debt Settlement | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 30, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 62,66 | +4,22 % | Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect? | ||
| NEWRON PHARMACEUTICALS | 12,750 | +0,79 % | Newron Pharmaceuticals: Jetzt zählt der FDA-Fahrplan | ||
| FILANA THERAPEUTICS | 0,856 | -3,17 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,765 | +8,03 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| COMPASS PATHWAYS | 10,100 | +3,59 % | Compass Pathfinder Limited: Compass Pathways gibt am 5. August 2026 die Finanzergebnisse für das zweite Quartal und das erste Halbjahr 2026 bekannt | Die Geschäftsführung von Compass wird um 8:00 Uhr ET (13:00 Uhr britischer Zeit) eine Telefonkonferenz abhalten
Compass Pathways plc (Nasdaq: CMPS), ein Biotechnologieunternehmen, das sich der... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 5,489 | 0,00 % | Achieve Life Sciences names manufacturing, quality executives | ||
| OPKO HEALTH | 1,120 | -0,88 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health | Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:... ► Artikel lesen | |
| OPUS GENETICS | 3,160 | -0,63 % | Opus Genetics, Inc.: Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease | Topline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) program Opus Genetics may... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 12,895 | +1,90 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen |
Das Unternehmen REVIVA PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,001 (-0,20 %) liegt der Kurs bei 0,351 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.